Brokerages Set Novo Nordisk A/S (NYSE:NVO) Target Price at $112.00

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) have earned an average rating of "Hold" from the eleven research firms that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $112.00.

Several equities research analysts have recently weighed in on the company. BMO Capital Markets reiterated a "market perform" rating and issued a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Wall Street Zen upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Saturday, June 14th. Guggenheim lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Hsbc Global Res raised shares of Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Dbs Bank lowered shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL boosted its stake in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after purchasing an additional 300 shares in the last quarter. Copeland Capital Management LLC lifted its holdings in Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after buying an additional 255 shares during the period. North Capital Inc. bought a new stake in Novo Nordisk A/S during the 1st quarter valued at $27,000. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter worth $29,000. Finally, Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S during the first quarter valued at about $30,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Down 0.0%

NVO traded down $0.01 during trading on Wednesday, reaching $69.81. The company had a trading volume of 7,899,944 shares, compared to its average volume of 7,257,356. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The business has a 50 day simple moving average of $69.52 and a 200-day simple moving average of $76.51. The stock has a market cap of $311.70 billion, a P/E ratio of 20.65, a PEG ratio of 1.23 and a beta of 0.64. Novo Nordisk A/S has a 52 week low of $57.00 and a 52 week high of $143.69.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion during the quarter. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.